155 related articles for article (PubMed ID: 29550682)
1. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.
Spatari C; Li W; Schinkel AH; Ragno G; Schellens JHM; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():204-208. PubMed ID: 29550682
[TBL] [Abstract][Full Text] [Related]
2. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Sparidans RW; Li W; Schinkel AH; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Nov; 161():136-143. PubMed ID: 30149189
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
5. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
[TBL] [Abstract][Full Text] [Related]
7. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
[TBL] [Abstract][Full Text] [Related]
9. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.
Sparidans RW; Kort A; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():24-9. PubMed ID: 27179188
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(28):2751-9. PubMed ID: 20829130
[TBL] [Abstract][Full Text] [Related]
11. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Dogan-Topal B; Li W; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():116-123. PubMed ID: 30802754
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():169-73. PubMed ID: 22476055
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
[TBL] [Abstract][Full Text] [Related]
15. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
Sparidans RW; Martens I; Valkenburg-van Iersel LB; den Hartigh J; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1851-6. PubMed ID: 21622034
[TBL] [Abstract][Full Text] [Related]
16. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():626-9. PubMed ID: 24216281
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
